Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

Jeffrey R Infante, Ronald L Korn, Lee S Rosen, Patricia LoRusso, Samuel S Dychter, Joy Zhu, Daniel C Maneval, Ping Jiang, H Michael Shepard, Gregory Frost, Daniel D Von Hoff, Mitesh J Borad and Ramesh K Ramanathan

Correction to: British Journal of Cancer (2018) 118, 156–167; doi: 10.1038/bjc.2017.327; published online 26 September 2017

There was an error in the description of the pharmacodynamics within the ‘Materials and methods’ section of this manuscript, and with the reference cited Printz et al (2017). The correct description is shown below:

Pharmacodynamics

HA plasma concentrations: The in vivo pharmacologic activity of PEGPH20 was evaluated by measuring plasma concentrations of HA following PEGPH20 administration. Blood samples were collected and analysed at a bioanalytical laboratory (MicroConstants, Inc., San Diego, CA, USA) using a validated assay (Printz et al, 2017). Plasma samples were enzymatically digested with chondroitinase ABC to hydrolyse different sizes of HA to the smallest HA-disaccharide, followed by derivatization with 4-nitrobenzyl hydroxylamine and analysis using high-performance liquid chromatography and tandem mass spectrometry. Plasma concentrations of HA were determined using reference standards and reported as nanograms of HA-disaccharide per millilitre of plasma. The lower limit of quantification was 42.3 ng ml⁻¹ (normal range, 10–100 ng ml⁻¹, Fraser et al, 1997).

There is no impact on the study results disclosed in the manuscript nor on the conclusions of the study. The results displayed in Figure 1 PEGPH20 Plasma Pharmacokinetics and Pharmacodynamics are consistent with the corrected method as described above.

The original HTML and PDF versions of this manuscript have been corrected, and can be found online and in the print issue.

REFERENCE

Printz MA, Babson B, Selvam P, Beyerlein D, Jiang P, Maneval DC, Sugarman BJ. A Quantitative Method for Determining Hyaluronan Content in Plasma by LC/MS/MS and Plasma HA as a Pharmacodynamic Marker for PEGylated-Hyaluronidase PH20 (PEGPH20) in a Phase 1b Trial for Pancreatic Ductal Adenocarcinoma [poster]. Exhibited at the American Association of Pharmaceutical Sciences National Biotechnology Conference; 1–3 May 2017; San Diego, CA, USA.

This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

© The Author(s) named above 2018

Published online 23 January 2018

Published by Springer Nature on behalf of Cancer Research UK.